Blueprint Medicines Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BLUEPRINT MEDICINES, and what generic alternatives to BLUEPRINT MEDICINES drugs are available?
BLUEPRINT MEDICINES has one approved drug.
There are seven US patents protecting BLUEPRINT MEDICINES drugs.
There are fifty-four patent family members on BLUEPRINT MEDICINES drugs in thirty-three countries and sixteen supplementary protection certificates in fourteen countries.
Summary for Blueprint Medicines
International Patents: | 54 |
US Patents: | 7 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 1 |
Drugs and US Patents for Blueprint Medicines
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-004 | Jun 16, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-003 | Jan 9, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-004 | Jun 16, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-005 | Jun 16, 2021 | RX | Yes | No | 11,999,744 | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Blueprint Medicines Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Cyprus | 1121182 | ⤷ Sign Up |
Israel | 287148 | ⤷ Sign Up |
Spain | 2683127 | ⤷ Sign Up |
Mexico | 2016004927 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Blueprint Medicines Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3057969 | 2190008-9 | Sweden | ⤷ Sign Up | PRODUCT NAME: AVAPRITINIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/20/1473 20200925 |
3057969 | PA2021003,C3057969 | Lithuania | ⤷ Sign Up | PRODUCT NAME: AVAPRITINIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/20/1473 20200924 |
3057969 | LUC00199 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: AVAPRITINIB ET SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/20/1473 20200925 |
3057969 | 122021000014 | Germany | ⤷ Sign Up | PRODUCT NAME: AVAPRITINIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/20/1473 20200924 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.